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Abstract
Background: Lupus erythematosus (LE) is a heterogeneous disease ranging from mainly skin-restricted manifestations
(discoid LE [DLE] and subacute cutaneous LE) to a progressive multisystem disease (systemic LE [SLE]). Genetic association
studies have recently identified several strong susceptibility genes for SLE, including integrin alpha M (ITGAM), also known
as CD11b, whereas the genetic background of DLE is less clear.
Principal Findings: To specifically investigate whether ITGAM is a susceptibility gene not only for SLE, but also for cutaneous
DLE, we genotyped 177 patients with DLE, 85 patients with sporadic SLE, 190 index cases from SLE families and 395
population control individuals from Finland for nine genetic markers at the ITGAM locus. SLE patients were further
subdivided by the presence or absence of discoid rash and renal involvement. In addition, 235 Finnish and Swedish patients
positive for Ro/SSA-autoantibodies were included in a subphenotype analysis. Analysis of the ITGAM coding variant
rs1143679 showed highly significant association to DLE in patients without signs of systemic disease (P-value = 4.73610211,
OR = 3.20, 95% CI = 2.23–4.57). Significant association was also detected to SLE patients (P-value = 8.2961026, OR = 2.14,
95% CI = 1.52–3.00), and even stronger association was found when stratifying SLE patients by presence of discoid rash (P-
value = 3.5961028, OR = 3.76, 95% CI = 2.29–6.18).
Significance: We propose ITGAM as a novel susceptibility gene for cutaneous DLE. The risk effect is independent of systemic
involvement and has an even stronger genetic influence on the risk of DLE than of SLE.
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Introduction
Lupus erythematosus (LE) is a complex autoimmune disease
with variable clinical course and manifestations. Cutaneous lupus
erythematosus (CLE) is a heterogeneous disease entity with
manifestations primarily confined to the skin. CLE can be
subdivided into chronic cutaneous lupus erythematosus, of which
discoid lupus erythematosus (DLE) is the most common form,
subacute cutaneous lupus erythematosus (SCLE), and acute
cutaneous lupus erythematosus (ACLE) [1]. ACLE is characteristic
for systemic lupus erythematosus (SLE) that manifests with severe
organ involvement and the presence of haematological and
immunological abnormalities, whereas well demarcated, scarring
plaques of the face, scalp and ears are often seen in DLE patients.
Mild extracutaneous involvement may be present in 14–27% of
patients with DLE [2], while only 5–10% progress to an overt SLE
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[3]. Lesions typical for DLE are seen in 15–20% of SLE patients
[4]. Population-based studies on the prevalence of CLE are rare,
but this condition is estimated to be 2–3 times more frequent than
SLE [5]. Although the pathogenic mechanisms underlying LE are
not yet entirely established, susceptibility is influenced by multiple
genetic and environmental factors, including ultraviolet (UV)
radiation, certain drugs and oestrogen [5].
A complex genetic component similar to that of SLE may also
underlie CLE [3]. The genetic architecture of CLE is poorly
understood, but polymorphisms in HLA genes, the TNF-a pro-
moter and complement molecules have been suggested as strong
candidates for CLE susceptibility [6]. We have recently shown
that the known SLE risk genes TYK2 and IRF5 also associate with
CLE [7].
ITGAM, a member of the immune complex processing pathway,
has been consistently replicated as an SLE susceptibility gene [8–
11]. The coding variant rs1143679 (R77H) was recently shown to
influence the risk of discoid rash in SLE patients [12]. ITGAM
(CD11b, Mac-1) encodes the a-chain of aMb2-integrin (CD11b/
CD18 or CR3), a cell surface receptor for multiple ligands, such as
complement 3 cleavage fragment and intercellular adhesion
molecule-1 (ICAM-1) [13]. The receptor is expressed on
neutrophils, macrophages and dendritic cells and is involved in
leukocyte adhesion, phagocytosis and regulation of apoptosis [13].
The exact disease aggravating mechanism is not known, but
altered interaction with ligands [10] as well as defects in leukocyte
trafficking and uptake of apoptotic cells or immune complexes
have been suggested [14]. As abnormal removal of apoptotic cells
plays an important role in evolving discoid lesions [6], ITGAM is a
plausible candidate gene not only for SLE, but also for cutaneous
DLE.
In the present study, we investigated the role of ITGAM in a
well-characterised cohort of DLE patients without signs of
systemic disease. The disease risk was further compared between
DLE and a cohort of SLE patients that was stratified for various
clinical subtypes.
Materials and Methods
Ethics statement
This study was conducted in accordance with the Declaration of
Helsinki Principles. All subjects gave their written informed
consent and the study was approved by the Ethical Review
Boards of Helsinki and Tampere University Central Hospitals,
Finland, and the Regional Human Ethics Committee at the
Karolinska University Hospital, the Institutional Ethics Board and
the Regional Ethics Board, Sweden.
Finnish patients and control individuals
Patients from two Finnish cohorts were included in the present
study. The recruitment of the case-control cohort and its clinical
characteristics have been described recently [15] (Table 1).
Altogether 177 DLE (76% women) and 85 SLE (93% women)
patients with LE-specific skin manifestations [16] diagnosed by a
dermatologist were recruited. The SLE family cohort included 190
probands (94% women) together with their family members (total
n = 236) [17]. The diagnosis of DLE was based on generally
accepted clinical, histological and immunofluorescence findings
[1] and exclusion of SCLE or SLE. In DLE patients without the
characteristic discoid rash (n= 14/177 patients) the diagnosis was
based on other phenotype-specific manifestations, such as absence
of antinuclear and/or double-stranded DNA antibodies, no signs
of extracutaneous disease and dermal perifollicular or perivascu-
lar mononuclear cell infiltrate [1] as well as careful clinical
examination of patients and patient chart review. Furthermore,
the histology and location of lesions usually in the head region, the
absence of systemic manifestations and negative laboratory
findings in these 14 cases supported the diagnosis of DLE rather
than SCLE or SLE. All SLE patients fulfilled the revised 1982
ACR classification criteria by Tan et al. [18] for SLE as confirmed
by a rheumatologist. A total of 356 anonymous Finnish controls
(49% women) comprising of unaffected spouses or common-law
spouses of patients and a collection of unrelated healthy
individuals were included in the study.
Swedish patients and control individuals
Patients from two separate Swedish cohorts were also utilised in the
present study. Swedish patients (n= 91) participating in a study
assessing the incidence and prevalence of SCLE in Stockholm in
1996–2002 [19] (Table 2) were included. In brief, patients positive for
Ro/SSA-autoantibodies (Ro-positive patients without signs of
systemic inflammation =21, DLE =2, SCLE =8, SLE =31,
Sjo¨gren’s syndrome [SS] =23, undifferentiated connective tissue
disease [UCTD] =6) reported their occurrence of photosensitivity
and skin symptoms in a questionnaire. Patients were examined
clinically (KP and FN) at the Department of Dermatology, Danderyd
Hospital, Stockholm, Sweden. Clinical data were completed based on
patient history and medical records. The diagnoses of DLE and
SCLE were based on the clinical and histopathological features [1].
The diagnoses of SLE and SS were based on the revised 1982 ACR
[18] and the revised European criteria [20], respectively. A diagnosis
Table 1. Clinical and demographic characteristics of the sets
of Finnish patient samples in this study.
Finnish case-control sample
DLE
(n=177)
SLE
(n =85)
SLE families
(n =236
patients)
Female 76 93 94
Mean age at onset (range; yrs) 42 (15–77) 36 (8–85) 29 (1–66)
Mean age at diagnosis (range; yrs) 45 (17–77) 40 (13–86) 33 (6–72)
Butterfly rash 11 72 51
Discoid rash 92 44 10
Annular SCLE lesions 1 12 na
Psoriasiform SCLE lesions 1 22 na
Photosensitivity 65 80 69
Mouth ulcers 4 18 18
Arthritis 2 64 83
Renal involvement 1 20 30
Leukopenia 7 37 68
Thrombocytopenia 5 17 16
Elevated antinuclear antibodies 28 98 na
Ro/SSA-antibody positivity1 25 66 na
La/SSB-antibody positivity1 4 31 na
Double-stranded DNA antibody
positivity
9 37 na
1Because of differences in laboratory methods and reference values, only
patients from Helsinki were included.
Na = not available.
Percentage (%) of patients with each phenotype is shown except for mean age,
which is shown in years (yrs).
doi:10.1371/journal.pone.0014212.t001
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of UCTD was based on signs and symptoms suggestive of a
connective tissue disease and the presence of antinuclear antibodies at
two different occasions [21]. Ro-autoantibodies were tested in
accredited laboratories in Stockholm using enzyme-linked immuno-
sorbent assay (ELISA) [19].
Another Swedish cohort consisted of patients with SS (n= 73)
fulfilling the revised European criteria [20] and attending the
Karolinska University Hospital, Stockholm, Sweden during 1998–
2008 (Table 2). The diagnosis was verified by a combination of
clinical examination by rheumatologists or medical doctors and a
questionnaire. Ro/SSA-autoantibodies were detected by an
ELISA using recombinant, purified Ro52 and Ro60 antigens [22].
A total of 164 Swedish patients with a diagnosis of a connective
tissue disease from two distinct cohorts were thus included in the
study. Out of these 164 genotyped patients, altogether 134 indi-
viduals were positive for Ro/SSA-autoantibodies and were further
utilised to evaluate the role of ITGAM in the presence of Ro
response. Swedish control samples (n=295; 90.5% women) were
population-based anonymous control individuals from the Epide-
miological Investigation of Rheumatoid Arthritis (EIRA) study [23].
Genotyping
After review of the literature regarding ITGAM published prior
to the initiation of this study [8–10], eleven single nucleotide
polymorphisms (SNP) at the ITGAM locus showing replicated
association to SLE in different populations were selected for
genotyping: rs1143679, rs9936831, rs9937837, rs9888879,
rs12928810, rs9888739, rs11860650, rs6565227, rs1143678,
rs4548893 and rs11574637.
Genotyping was performed according to manufacturer’s
instructions using Sequenom iPLEX Gold chemistry [24]
(Sequenom Inc., San Diego, California, USA). Assay design and
genotyping were performed in the genotyping core facility at
Karolinska Institutet, Huddinge, Sweden. The average genotyping
success rate of each marker was 94% for the Finnish case-control
cohort, 96% for the Finnish SLE families and 94% for the Swedish
case-control cohort; all markers were in Hardy-Weinberg equili-
brium (P.0.05) in controls. The markers rs12928810 (only in SLE
families), rs6565227 and rs1143678 had success rates below our
threshold (,85%) and were thus excluded.
Statistical analysis
Haploview v. 4.0 [25] was used to study linkage disequilibrium
(LD) patterns, estimate haplotypes (Figure 1A–C) and perform
association analyses. To increase the statistical power of the
association analysis, the sporadic SLE cases (n = 85) were analysed
in combination with unrelated probands (n = 190) from the SLE
family cohort, thus giving a total of 275 independent Finnish SLE
patients and 356 controls for analysis. Allele and haplotype counts
were compared between patients and controls by chi-square test,
and permutation testing (10 000 iterations) as implemented into
Haploview was performed in order to obtain a measure of
significance corrected for multiple testing bias. Due the strong LD
(Figure 1A) throughout the ITGAM locus and thus dependence
between markers, traditional Bonferroni correction would likely to
be overly conservative. Two-tailed, uncorrected P-values are
reported in the Results section, and odds ratios (OR) with their
respective 95% confidence intervals (CI) were calculated using
GraphPad Prism v.4.03 (GraphPad Software Inc., La Jolla, CA,
USA).
Patient stratification for subphenotype analysis
Finnish SLE patients were further stratified by presence of
discoid rash (n= 55) and renal involvement (n = 76) defined as
fulfilment of the ACR renal criteria [18]. Finnish (n = 101) and
Swedish (n = 134) patients positive for Ro/SSA-autoantibodies
were first analysed individually and further in combination
(n= 235) as a pooled dataset in order to study the association
between ITGAM and immunological factors [12,26]. Ro-autoan-
tibodies were selected for detailed investigation, because they may
have pathobiological importance in apoptosis and phagocytosis
[27] similarly to ITGAM, and prognostic value for predicting
systemic inflammatory disease [28]. Furthermore, several genetic
regions harbouring genes for adhesion molecules have shown
evidence of association to DLE in the presence of Ro-
autoantibodies [6] and the disease progression may be highly
dynamic in Ro-positive patients [29].
Power calculations
The power to detect association of ITGAM to different forms of
LE in our sample sets was estimated using the online Power for
Association With Error program (http://linkage.rockefeller.edu/
pawe/). We assumed a risk allele frequency of 0.185, an OR of
1.70 [11] and alpha 0.05. The average power to detect association
of ITGAM polymorphisms was 84% in DLE and 91% in SLE. In
subphenotype analyses when using reported reference values [12],
the power to detect association of rs1143679 was 77% in SLE
with discoid rash and 92% in SLE with renal involvement. For
Table 2. Clinical and demographic characteristics of the
Swedish sample sets in this study.
Swedish case-control sample
Connective tissue
disease patients
(n =91)1
Sjo¨gren’s
syndrome patients
(n =73)2
Female 91 95
Mean age at onset (range; yrs) 58 (18–83)3 na
Mean age at diagnosis
(range; yrs)
na 52 (20–87)
Butterfly rash 13 na
Discoid rash 19 na
Annular SCLE lesions 14 na
Psoriasiform SCLE lesions 0 na
Photosensitivity 100 na
Mouth ulcers na na
Arthritis 5 23
Renal involvement 5 4
Leukopenia na 18
Thrombocytopenia na 3
Elevated antinuclear antibodies 74 55
Ro/SSA antibody positivity 100 59
La/SSB antibody positivity 38 38
Double-stranded DNA antibody
positivity
13 na
1Ro/SSA positive patients without signs of systemic inflammation = 21, DLE = 2,
SCLE = 8, SLE = 31, SS = 23, UCTD =6 from the study of Popovic et al. [19].
2SS patients, data provided by Prof. Marie Wahren-Herlenius, MD, PhD, Dept. of
Medicine, Rheumatology Unit, Karolinska Institutet, Solna, Sweden.
3Mean age at initial testing for Ro/SSA-autoantibodies [19].
Na = data not available.
Percentage (%) of patients is shown except for mean age, which is shown in
years (yrs).
doi:10.1371/journal.pone.0014212.t002
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Ro-positive Finnish, Swedish and the pooled dataset a power of
70%, 75% and 95%, respectively, was obtained when previously
reported risk estimates were assumed [11].
Results
Nine ITGAM SNPs were successfully genotyped in three datasets
corresponding to two different LE subgroups (Finnish patients with
DLE or SLE) and control individuals. Subphenotype analyses were
further performed to investigate the role of ITGAM in specific
clinical manifestations. These analyses showed that the magnitude
of association was strongest in cutaneous DLE (P-value
$3.7610211; uncorrected P-values are reported), followed by
SLE patients with discoid rash (P-value $3.961029) and all SLE
patients together (P-value $8.261026) (Table 3). The associations
were more modest in SLE patients with renal involvement (P-value
$5.861025) (Table 4), in Finnish (P-value $6.361026) and
Swedish (P-value $0.01) Ro/SSA-positive patients as well as in
the pooled dataset positive for Ro-antibodies (P-value $6.461026)
(Table 5). As hypothesised, the marker rs1143679 (R77H) showed
the strongest association in DLE, SLE and SLE with discoid rash
(P-value range from 4.7610211 to 8.361026) (Table 3). The same
marker was observed to reach a more humble, although statistically
significant, effect in subphenotype analyses (P-value range from
6.461026 to 0.04) (Tables 4 and 5), which may mirror the impact of
sample size. In addition to rs1143679, the eight other markers
studied were observed to associate significantly in Finnish patients
(Tables 3, 4, 5), whereas Swedish patients showed borderline
association (Table 5). In general, the risk allele frequencies were
somewhat higher in DLE, and SLE patients with discoid rash
compared to unstratified SLE patients in our study (Table 3) or
previous studies, whereas our control individuals had frequencies
similar to other control populations of European origin [8,10,11]. A
similar increase in ORs was also observed, the risk estimates being
highest in SLE patients with discoid rash (range 2.46–3.95) and in
DLE patients (range 1.65–3.20) followed by unstratified SLE
patients (range 1.52–2.14) (Table 3), SLE patients with renal
involvement (range 1.82–2.53) (Table 4) and Ro-positive patients
(range 1.37–2.03 in the pooled dataset) (Table 5).
Haplotype associations
The haplotype structure of ITGAM was further investigated in
each set of samples, but this neither improved statistical significance
nor yielded any further information (Figure 1 B). One high risk
Figure 1. Linkage disequilibrium (LD) patterns across the ITGAM-ITGAX locus and haplotype association analysis results. A) LD plot of
the genotyped ITGAM region on chromosome 16p11 (HapMap CEU data from build 36). Darker colour denotes higher LD (D’). Asterisks indicate single
nucleotide polymorphism (SNP) markers genotyped in all datasets in the study. B) Haplotype associations for markers conferring risk for cutaneous
DLE, SLE with discoid rash and unstratified SLE. Haplotype 2 is associated with increased, and haplotypes 1 and 3 with decreased risk of cutaneous
DLE, SLE with discoid rash, and SLE. Haplotype 2 carries the minor allele A (in bold) of rs1143679, shown in previous studies to tag risk haplotypes for
SLE. Significant P-values are indicated in bold. The order of SNPs in haplotypes is as follows: rs1143679 - rs9936831 - rs9937837 - rs9888879 -
rs12928810 - rs9888739 - rs11860650 - rs4548893 - rs11574637. C) LD plot of the genotyped SNPs in the DLE dataset. Similar LD patterns were
observed in unstratified SLE and in SLE patients stratified for discoid rash and renal involvement as well as in Ro/SSA-positive patients (data not
shown).
doi:10.1371/journal.pone.0014212.g001
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haplotype carrying the minor allele A of rs1143679 (ATG-
CATTTC; P-value = 7.4610212, OR =3.33, 95% CI =2.33–
4.75) and two haplotypes with a protective effect (GATTGCCCT;
P-value = 7.661025, OR =0.58, 95% CI =0.44–0.76, and
GAGTGCCCT; P-value = 1.761022, OR =0.57, 95% CI
=0.36–0.92), reaching statistical significance, were found in DLE
(Figure 1B). The same risk haplotype with equally strong effect on
risk was observed in SLE (OR =2.20, 95% CI =1.57–3.09), in
SLE patients with discoid rash (OR =4.03, 95% CI =2.47–6.59)
(Figure 1B) and in SLE patients with renal involvement (OR =2.59,
95% CI =1.60–4.21) (data not shown). Finnish and Swedish
patients positive for Ro/SSA-autoantibodies analysed either
separately or pooled together showed the same haplotype patterns
as DLE and SLE patients (data not shown). In line with other
studied patient groups, the risk conferring ATGCATTTC haplo-
type showed evidence of strong association (P=3.061026, OR
=2.08, 95% CI =1.52–2.83) within Ro-positive patients when
Finnish and Swedish subjects were analysed in combination.
Table 3. Single marker association results in Finnish DLE, in SLE with discoid rash and in SLE patients.
Marker Alleles
Associated
allele
Controls
(n =356) DLE (n =177) SLE with discoid rash (n =55) SLE (n=275)
Freq. Freq.
P-value
(corrected)
OR
(95% CI) Freq.
P-value
(corrected)
OR
(95% CI) Freq.
P-value
(corrected)
OR
(95% CI)
rs1143679 A/G A 0.10 0.26 4.73610211
(,0.0001)
3.20
(2.23–4.57)
0.29 3.5961028
(,0.0001)
3.76
(2.29–6.18)
0.19 8.2961026
(,0.0001)
2.14
(1.52–3.00)
rs9936831 T/A T 0.10 0.26 2.14610210
(,0.0001)
3.03
(2.13–4.31)
0.31 3.9961029
(,0.0001)
3.95
(2.44–6.40)
0.19 1.3261025
(,0.0001)
2.08
(1.49–2.90)
rs9937837 G/T G 0.24 0.34 6.0061024
(0.004)
1.65
(1.24–2.20)
0.43 1.9761025
(5.0061024)
2.46
(1.61–3.76)
0.32 1.2061023
(0.01)
1.52
(1.18–1.96)
rs9888879 C/T C 0.10 0.26 7.57610211
(,0.0001)
3.06
(2.16–4.34)
0.31 3.3861029
(,0.0001)
3.93
(2.43–6.34)
0.19 1.1061025
(,0.0001)
2.06
(1.49–2.86)
rs12928810 A/G A 0.10 0.23 8.0361028
(,0.0001)
2.77
(1.89–4.07)
na1 na na na1 na na
rs9888739 T/C T 0.10 0.25 2.91610210
(,0.0001)
3.01
(2.12–4.29)
0.30 1.0361028
(,0.0001)
3.88
(2.38–6.33)
0.18 7.5261025
(7.0061024)
1.96
(1.40–2.74)
rs11860650 T/C T 0.10 0.27 3.71610211
(,0.0001)
3.13
(2.21–4.43)
0.31 1.1061028
(,0.0001)
3.81
(2.35–6.18)
0.19 3.3661025
(1.0061024)
1.99
(1.43–2.77)
rs4548893 T/C T 0.15 0.32 1.10610210
(,0.0001)
2.74
(2.00–3.74)
0.35 2.6161027
(,0.0001)
3.14
(2.00–4.94)
0.22 9.0061024
(0.008)
1.64
(1.22–2.21)
rs11574637 C/T C 0.15 0.30 2.3761029
(,0.0001)
2.57
(1.87–3.52)
0.37 1.9861028
(,0.0001)
3.43
(2.19–5.37)
0.22 5.0061024
(0.004)
1.69
(1.25–2.27)
The frequency of the associated allele in controls and cases is shown, as well as its uncorrected P-value and P-value corrected for multiple testing (in parentheses) as well
as odds ratio (OR) with 95% confidence interval (CI).
Abbreviations: DLE, discoid lupus erythematosus; SLE, systemic lupus erythematosus.
1The marker has success below the study threshold (,85%) and was excluded from analysis in SLE.
doi:10.1371/journal.pone.0014212.t003
Table 4. Single marker association results in Finnish SLE patients with renal involvement.
Allele associations
Marker Alleles Associated allele Controls (n =356) Patients (n=76)
Freq. Freq. P-value (corrected) OR (95% CI)
rs1143679 A/G A 0.10 0.21 1.0061024 (0.003) 2.49 (1.54–4.01)
rs9936831 T/A T 0.10 0.22 1.0061024 (0.003) 2.43 (1.51–3.89)
rs9937837 G/T G 0.24 0.35 0.005 (0.03) 1.74 (1.18–2.57)
rs9888879 C/T C 0.10 0.23 5.8361025 (0.002) 2.53 (1.59–4.02)
rs9888739 T/C T 0.10 0.20 0.001 (0.01) 2.22 (1.35–3.65)
rs11860650 T/C T 0.10 0.23 9.7161025 (0.002) 2.49 (1.55–3.97)
rs4548893 T/C T 0.15 0.25 0.002 (0.02) 1.99 (1.29–3.07)
rs11574637 C/T C 0.15 0.24 0.008 (0.05) 1.82 (1.16–2.83)
The frequency of the associated allele in controls and cases is shown, as well as its uncorrected P-value, and P-value corrected for multiple testing (in parentheses) as
well as odds ratio (OR) with 95% confidence interval (CI). The marker rs12928810 has success below the study threshold (,85%) and was excluded from analysis. Renal
involvement is defined as fulfilment of the ACR renal criteria [18].
doi:10.1371/journal.pone.0014212.t004
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Discussion
In the present study we have shown that polymorphisms at the
ITGAM locus increase the risk of cutaneous DLE three-fold
compared to healthy control individuals, and the magnitude of the
association is five times higher in DLE than in SLE patients. To
our knowledge, the current study is the first to address the role of
ITGAM in a clinically verified cohort of cutaneous DLE patients
without signs of systemic disease. We furthermore replicated in our
series of SLE patients the recent observation of Kim-Howard et al.
[12] that the coding variant rs1143679 (R77H) may influence the
risk of discoid rash in SLE.
The marker rs1143679 showed strong association in DLE, in SLE
patients with discoid rash and in all SLE patients together. In patient
subgroups stratified for renal involvement or Ro/SSA-autoantibody
positivity more modest association was observed. The ITGAM exon
3 variant rs1143679 was originally identified and replicated in three
different populations [10] parallel with GWA studies [8,9]. To date,
its robust association with SLE has been confirmed in a meta-
analysis encompassing populations across the world [11], but it has
not previously been studied in the cutaneous forms of LE.
Several variants within ITGAM and the adjacent ITGAX gene
(Table 3) were found to associate strongly to DLE and also to SLE
with discoid rash. It has, however, been speculated that these multiple
association signals are mainly reflecting the strong LD between
rs1143679 and nearby markers [11] (Figure 1A), as any haplotype
carrying the risk allele A at rs1143679 within ITGAM confers risk for
SLE [10]. Our haplotype analysis is in line with this (Figure 1B).
Two previous studies have systematically screened several clinical
subphenotypes of SLE, including patients with renal and immuno-
logical disorders, for association to ITGAM [12,26]. In line with
these reports we observed increased risk in SLE patients with renal
involvement. We further investigated the relationship between
ITGAM and immunological disorders in a group of patients positive
for Ro/SSA-autoantibodies and found significant association in
accordance with findings from a previous study [26]. Possible
pathomechanisms underlying these associations have been pro-
posed [12,26], but not yet established. Interestingly, Ro-autoanti-
bodies and the protein product of the ITGAM gene function on the
same biological pathways of apoptosis and phagocytosis. It has
recently been shown that high Ro52 expression induces apoptosis,
and it has been postulated that apoptotic cell opsonisation with Ro-
positive sera might rather prevent that than facilitate phagocytosis
[27]. However, as Ro-autoantibodies are not exclusive to LE, it is
difficult to draw definitive conclusions about this undoubtedly
complex relationship between ITGAM, Ro-positivity and LE based
on observations by us and others [26].
The only ITGAM variant for which a functional role has been
proposed to date is the previously mentioned rs1143679. This
polymorphism results in an amino acid change (R77H) that may
alter the structure and function of the receptor protein and further
affect its ligand binding activities [10] thus influencing, for
instance, ICAM-1 mediated leukocyte recruitment [10], essential
in the formation of the inflammatory lesions seen in DLE
[6,14,18]. Interestingly, ICAM-1 has been shown to be involved
in the pathogenesis of various types of skin disease [30] especially
in the presence of Ro/SSA-response [3] and it is upregulated in
skin lesions of patients with DLE [30].
ITGAM is also interesting in the context of the photosensitivity
generally observed in DLE patients [6]. UV-B irradiation initiates
a cascade of proinflammatory events in the skin [5,31]. Upon UV
exposure, macrophages expressing ITGAM invade the dermis and
epidermis [32,33], leading to a depletion of antigen presenting
cells [32,34]. There is a delay in dendritic cell differentiation in
UV-exposed skin [34] and antigenic tolerance is induced [31].
Furthermore, IL-10, a cytokine known to trigger DLE, and discoid
rash in SLE [35], is upregulated upon UV exposure. Genetic
alterations of ITGAM function(s) along this pathway may therefore
lead to defects in the suppression of dendritic cell differentiation in
combination with high IL-10 production and induce inadvertent
immune reactions in DLE patients. Furthermore, UV induces also
the production of TNF-a [36], a proinflammatory cytokine that
has been, in combination with pronounced IL-10 production,
suggested to increase DLE risk [35]. Moreover, TNF-a primes
neutrophils to migrate into inflammatory sites through the
upregulation of CD11b/CD18 (aMb2-integrin) [37].
In the present study, a panel of ITGAM polymorphisms was
specifically tested for association to cutaneous DLE in a well-
described cohort of patients that is one of the largest reported. Our
study has contributed with ITGAM to the short list of genes shown
to be associated with DLE. The genetic background of CLE, and
that of DLE in particular, is poorly characterised. Furthermore,
studies on this disease have been difficult to evaluate and replicate
due to low sample sizes non-reporting of risk effect estimates.
There are only a few confirmed risk loci, including HLA genes, the
TNF-a promoter and complement factors [6]. However, TNF-a
shows only modest association [36,38] and the association may be
merely due to the strong LD across the HLA region. These sparse
data indicate that the genetic background of DLE and other forms
of CLE may be very complex and require further studies. Only a
few studies have addressed the gender differences in CLE
pathogenesis [39] and it is still unclear, what the effect of sex in
this disorder may be. Women are known to respond to infection,
vaccination and trauma with increased antibody production and a
more T helper cell 2 predominant immune response, whereas a T
helper cell 1 response and inflammation are usually more severe in
men [40]. Thus, it is reasonable to assume that, especially in the
function of above mentioned immune system related genes, there
would be alterations in the disease mechanisms between female
and male subjects. However, investigating this in future studies is a
challenging task given the female preponderance of the disease,
and carefully matched control individuals are needed as well.
In conclusion, we have demonstrated here a strong novel
association between ITGAM variants and cutaneous DLE without
signs of systemic disease. These variants function independently of
the systemic disease and increase substantially the risk of DLE with
an effect even higher than in SLE. Our results further strengthen
the hypothesis that different forms of LE are not genetically
distinct entities even though their clinical course varies. Based on
its function(s), ITGAM may predispose to DLE through impaired
phagocytosis, leukocyte trafficking or immune suppression in UV-
exposed skin. The exact mechanisms by which ITGAM contributes
to the disease pathogenesis and how its expression may be altered
in affected DLE skin, warrant further studies.
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